Atopic Dermatitis (AD) Treatment Market By Drug (Anti-Inflammatory Agents, Antihistamines, Immunomodulators, Interleukin Inhibitors, Topical Phosphodiesterase-4 (PDE-4) Inhibitors, Antiviral Agents, Antibiotics) - Growth, Future Prospects, And Competitive Analysis, 2025 -2033

03 Sep 2017 Format PDF icon PPT icon XLS icon Request Sample
1. Preface
1.1. Report Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. Key Offerings
1.2. Market Segmentation
1.3. Research Methodology
1.3.1. Phase I - Secondary Research
1.3.2. Phase II - Primary Research
1.3.3. Phase III - Expert Panel Review
1.3.4. Assumptions
1.3.5. Approach Adopted

2. Executive Summary
2.1. Market Snapshot: Global Atopic Dermatitis (AD) Treatment Market
2.3. Global Atopic Dermatitis (AD) Treatment Market, By Drug, 2025 (US$ Million)
2.4. Global Atopic Dermatitis (AD) Treatment Market, By Geography, 2025 (US$ Million)
2.5. Attractive Investment Proposition by Geography, 2025

3. Atopic Dermatitis (AD) Treatment Market: Competitive Analysis
3.1. Market Positioning of Key Atopic Dermatitis (AD) Treatment Market Vendors
3.2. Strategies Adopted by Atopic Dermatitis (AD) Treatment Market Vendors

4. Atopic Dermatitis (AD) Treatment Market: Macro Analysis & Market Dynamics
4.1. Introduction
4.2. Global Atopic Dermatitis (AD) Treatment Market Value, 2024 - 2034, (US$ Million)
4.3. Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Key Challenges
4.3.4. Key Opportunities
4.4. Impact Analysis of Drivers and Restraints
4.5. Porter's Five Force Model
4.5.1. Supplier Power
4.5.2. Buyer Power
4.5.3. Threat Of Substitutes
4.5.4. Threat Of New Entrants
4.5.5. Competitive Rivalry
4.6. PESTEL Analysis
4.6.1. Political Landscape
4.6.2. Economic Landscape
4.6.3. Social Landscape
4.6.4. Technology Landscape
4.6.5. Environmental Landscape
4.6.6. Legal Landscape

5. Atopic Dermatitis (AD) Treatment Market: By Drug, 2024-2034, USD (Million)
5.1. Market Overview
5.2. Growth & Revenue Analysis: 2025 Versus 2034
5.3. Market Segmentation
5.3.1. Anti-inflammatory agents
5.3.1.1. Corticosteroids
5.3.1.2. Calcineurin Inhibitors
5.3.2. Antihistamines
5.3.3. Immunomodulators
5.3.4. Interleukin Inhibitors
5.3.5. Topical Phosphodiesterase-4 (PDE-4) Inhibitors
5.3.6. Antiviral agents
5.3.7. Antibiotics

6. North America Atopic Dermatitis (AD) Treatment Market, 2024-2034, USD (Million)
6.1. Market Overview
6.2. Atopic Dermatitis (AD) Treatment Market: By Drug, 2024-2034, USD (Million)
6.3. Atopic Dermatitis (AD) Treatment Market: By Region, 2024-2034, USD (Million)
6.3.1.North America
6.3.1.1. U.S.
6.3.1.1.1. Atopic Dermatitis (AD) Treatment Market: By Drug, 2024-2034, USD (Million)
6.3.1.2. Canada
6.3.1.2.1. Atopic Dermatitis (AD) Treatment Market: By Drug, 2024-2034, USD (Million)
6.3.1.3. Rest of North America
6.3.1.3.1. Atopic Dermatitis (AD) Treatment Market: By Drug, 2024-2034, USD (Million)

7. UK and European Union Atopic Dermatitis (AD) Treatment Market, 2024-2034, USD (Million)
7.1. Market Overview
7.2. Atopic Dermatitis (AD) Treatment Market: By Drug, 2024-2034, USD (Million)
7.3. Atopic Dermatitis (AD) Treatment Market: By Region, 2024-2034, USD (Million)
7.3.1.UK and European Union
7.3.1.1. UK
7.3.1.1.1. Atopic Dermatitis (AD) Treatment Market: By Drug, 2024-2034, USD (Million)
7.3.1.2. Germany
7.3.1.2.1. Atopic Dermatitis (AD) Treatment Market: By Drug, 2024-2034, USD (Million)
7.3.1.3. Spain
7.3.1.3.1. Atopic Dermatitis (AD) Treatment Market: By Drug, 2024-2034, USD (Million)
7.3.1.4. Italy
7.3.1.4.1. Atopic Dermatitis (AD) Treatment Market: By Drug, 2024-2034, USD (Million)
7.3.1.5. France
7.3.1.5.1. Atopic Dermatitis (AD) Treatment Market: By Drug, 2024-2034, USD (Million)
7.3.1.6. Rest of Europe
7.3.1.6.1. Atopic Dermatitis (AD) Treatment Market: By Drug, 2024-2034, USD (Million)

8. Asia Pacific Atopic Dermatitis (AD) Treatment Market, 2024-2034, USD (Million)
8.1. Market Overview
8.2. Atopic Dermatitis (AD) Treatment Market: By Drug, 2024-2034, USD (Million)
8.3. Atopic Dermatitis (AD) Treatment Market: By Region, 2024-2034, USD (Million)
8.3.1.Asia Pacific
8.3.1.1. China
8.3.1.1.1. Atopic Dermatitis (AD) Treatment Market: By Drug, 2024-2034, USD (Million)
8.3.1.2. Japan
8.3.1.2.1. Atopic Dermatitis (AD) Treatment Market: By Drug, 2024-2034, USD (Million)
8.3.1.3. India
8.3.1.3.1. Atopic Dermatitis (AD) Treatment Market: By Drug, 2024-2034, USD (Million)
8.3.1.4. Australia
8.3.1.4.1. Atopic Dermatitis (AD) Treatment Market: By Drug, 2024-2034, USD (Million)
8.3.1.5. South Korea
8.3.1.5.1. Atopic Dermatitis (AD) Treatment Market: By Drug, 2024-2034, USD (Million)
8.3.1.6. Rest of Asia Pacific
8.3.1.6.1. Atopic Dermatitis (AD) Treatment Market: By Drug, 2024-2034, USD (Million)

9. Latin America Atopic Dermatitis (AD) Treatment Market, 2024-2034, USD (Million)
9.1. Market Overview
9.2. Atopic Dermatitis (AD) Treatment Market: By Drug, 2024-2034, USD (Million)
9.3. Atopic Dermatitis (AD) Treatment Market: By Region, 2024-2034, USD (Million)
9.3.1.Latin America
9.3.1.1. Brazil
9.3.1.1.1. Atopic Dermatitis (AD) Treatment Market: By Drug, 2024-2034, USD (Million)
9.3.1.2. Mexico
9.3.1.2.1. Atopic Dermatitis (AD) Treatment Market: By Drug, 2024-2034, USD (Million)
9.3.1.3. Rest of Latin America
9.3.1.3.1. Atopic Dermatitis (AD) Treatment Market: By Drug, 2024-2034, USD (Million)

10. Middle East and Africa Atopic Dermatitis (AD) Treatment Market, 2024-2034, USD (Million)
10.1. Market Overview
10.2. Atopic Dermatitis (AD) Treatment Market: By Drug, 2024-2034, USD (Million)
10.3. Atopic Dermatitis (AD) Treatment Market: By Region, 2024-2034, USD (Million)
10.3.1.Middle East and Africa
10.3.1.1. GCC
10.3.1.1.1. Atopic Dermatitis (AD) Treatment Market: By Drug, 2024-2034, USD (Million)
10.3.1.2. Africa
10.3.1.2.1. Atopic Dermatitis (AD) Treatment Market: By Drug, 2024-2034, USD (Million)
10.3.1.3. Rest of Middle East and Africa
10.3.1.3.1. Atopic Dermatitis (AD) Treatment Market: By Drug, 2024-2034, USD (Million)

11. Company Profile
11.1. AbbieVie Inc. (Company Overview, Financial Performance, Product Portfolio, Strategic Initiatives)
11.2. Encore Dermatology Inc.
11.3. F. Hoffmann-La Roche AG
11.4. Glaxosmithkline plc.
11.5. LEO Pharma A/S
11.6. Medimmune LLC. (Astrazeneca)
11.7. Novartis AG
11.8. Pfizer Inc.
11.9. Regeneron Pharmaceuticals Inc.
11.10. Sanofi S.A.
11.11. Valeant Pharmaceuticals Inc.
Choose Licence Type
$4500.00
$6500.00
$9000.00
Filter

Key Sectors